As reported on PharmaBiz, Omnix Medical has reached a key clinical milestone with the initiation of patient dosing in a phase II study of its lead antimicrobial candidate, OMN6. The investigational therapy is designed to address severe infections caused by Acinetobacter baumannii, a pathogen widely recognized for its resistance to multiple antibiotics and its association with high mortality in hospitalized patients.
The first participants in the trial were enrolled at several leading Israeli medical centers, including Rabin Medical Center (Beilinson Hospital), Samson Assuta Ashdod University Hospital, and Shamir Medical Center. This study marks a critical step toward establishing clinical proof of concept for the novel therapy.
Study Design and Objectives
The ongoing phase IIa trial is a randomized, double-blind, placebo-controlled study with a dose-ranging design. Conducted across multiple international sites, it focuses on patients suffering from hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) linked to Acinetobacter baumannii complex, including strains resistant to carbapenems. These pathogens are classified by the World Health Organization as among the most urgent threats to global health.
The trial aims to evaluate the safety and tolerability of OMN6 while also examining its pharmacokinetic profile. Investigators are seeking to determine optimal dosing strategies for further clinical development.
Novel Mechanism Targets Unmet Need
OMN6 represents a first-in-class antimicrobial peptide engineered to combat multidrug-resistant Gram-negative bacteria through a mechanism distinct from conventional antibiotics. Rather than interfering with bacterial metabolic processes, the compound directly disrupts the integrity of bacterial membranes, leading to rapid cell destruction.
This membrane-targeting approach is designed to overcome traditional resistance mechanisms and reduce the likelihood of new resistance emerging. OMN6 selectively binds to bacterial membranes due to their unique lipid composition, forming pores that destabilize and ultimately kill the pathogen.
Clinical Context and Expert Perspectives
Infections caused by carbapenem-resistant A. baumannii are particularly challenging to treat, with mortality rates in critically ill patients reportedly reaching as high as 60%. Experts have emphasized the urgent need for innovative therapies that operate through new biological pathways.
Professor Keith Kaye of Rutgers Robert Wood Johnson Medical School highlighted the growing threat posed by multidrug-resistant Gram-negative organisms, noting that current treatment options are often inadequate. Similarly, Professor Yehuda Carmeli of Tel Aviv Medical Center emphasized that therapies like OMN6, which physically destroy bacterial cells, may represent an important advancement in addressing these infections.
Company Background and Development Path
Founded in 2015, Omnix Medical focuses on developing next-generation anti-infectives based on engineered antimicrobial peptides. The company has secured support from multiple funding bodies, including the Israeli Innovation Authority, the European Union’s Horizon 2020 program, and the U.S. National Institutes of Health.
OMN6 has already completed phase I testing and is now progressing through mid-stage clinical evaluation. Its development reflects broader efforts in the biotech sector to tackle the escalating global crisis of antimicrobial resistance through alternative therapeutic strategies.
Outlook
With patient dosing now underway, the phase II study of OMN6 will provide important data on its clinical performance in a high-risk population. If successful, the therapy could represent a new frontline option for treating life-threatening infections where current antibiotics fall short.
